Form 4: Phio Pharma Director Granted 14,000 RSUs

Phio Pharmaceuticals director David H. Deming was granted 14,000 restricted stock units, vesting in one year, as disclosed in a recent SEC Form 4 filing.

Summary

• David H. Deming, a director of Phio Pharmaceuticals Corp., was granted 14,000 shares of common stock in the form of restricted stock units (RSUs).
• These RSUs were granted on September 11, 2025, at a price of $0 per share.
• The shares underlying the restricted stock units will vest on the first annual anniversary of the grant date.
• Following this transaction, Deming beneficially owns 14,000 shares, which include these unvested RSUs.
• An associated Power of Attorney, executed on September 4, 2025, authorizes Lisa C. Carson and Irina Abbas to handle SEC filings for David H. Deming.

Sentiment

Score: 6

Explanation: The grant of restricted stock units to a director is a positive event as it aligns management's interests with long-term shareholder value, indicating commitment and incentivizing performance. It's a routine compensation event, not a major operational or financial breakthrough.

Positives

• Director David H. Deming received a grant of 14,000 restricted stock units, aligning his interests with long-term shareholder value.

Future Outlook

The 14,000 restricted stock units granted to Director David H. Deming are scheduled to vest on the first annual anniversary of the grant date, aligning future compensation with company performance.

Industry Context

The grant of restricted stock units to a director is a common practice in the biotechnology and pharmaceutical industry to incentivize long-term commitment and align executive interests with shareholder returns, particularly for companies like Phio Pharmaceuticals Corp. which are often in development stages.

Comparison to Industry Standards

• Granting restricted stock units (RSUs) to directors is a standard compensation practice across various industries, including biotechnology.
• This method is widely used to retain talent and align director incentives with long-term company performance and shareholder value.
• While the specific number of units (14,000) and the vesting schedule (one-year anniversary) are company-specific, the mechanism itself is consistent with industry benchmarks for non-cash director compensation.

Corporate Governance

Related Party Transactions

• Grant of 14,000 restricted stock units to David H. Deming, a director of Phio Pharmaceuticals Corp., as a form of compensation.

Stakeholder Impact

• Shareholders: The grant of restricted stock units aligns the director's financial interests with the long-term performance and value creation for shareholders.

Next Steps

• The next key event related to this filing is the vesting of the 14,000 restricted stock units on the first annual anniversary of the grant date, September 11, 2026.

Key Dates

Recommendation

The grant of restricted stock units to a director is a standard compensation practice that aligns the director's interests with the company's long-term performance. While positive for corporate governance and incentive alignment, it does not represent a material operational or financial development that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while monitoring future company performance and strategic developments.

Keywords

Phio Pharmaceuticals, PHIO, David H. Deming, Director, Restricted Stock Units, RSU, Stock Grant, Insider Transaction, Form 4, SEC Filing, Corporate Governance